In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations

Samuel Shelburne; Daniel M. Musher; Kristina Hulten; Heather Ceasar; Michael Y. Lu; Imran Bhaila; Richard J. Hamill

doi:10.1128/AAC.48.10.4016-4019.2004

In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations

Samuel Shelburne, Daniel M. Musher, Kristina Hulten, Heather Ceasar, Michael Y. Lu, Imran Bhaila, Richard J. Hamill

Research Institute

Research output: Contribution to journal › Article

56 Scopus citations

Abstract

This study employs time-kill techniques to examine the most common drug combinations used in the therapy of methicillin-resistant Staphylococcus aureus (MRSA) infections, vancomycin plus either gentamicin or rifampin. Community-associated MRSA were more likely to be synergistically inhibited by combinations of vancomycin and gentamicin versus vancomycin alone compared to inhibition associated with hospital-acquired strains.

Original language	English (US)
Pages (from-to)	4016-4019
Number of pages	4
Journal	Antimicrobial Agents and Chemotherapy
Volume	48
Issue number	10
DOIs	https://doi.org/10.1128/AAC.48.10.4016-4019.2004
State	Published - Oct 2004

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)
Infectious Diseases

Access to Document

10.1128/AAC.48.10.4016-4019.2004

Fingerprint Dive into the research topics of 'In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations'. Together they form a unique fingerprint.

Cite this

@article{7437c38eb82f4f8087148fa2613ff10b,

title = "In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations",

abstract = "This study employs time-kill techniques to examine the most common drug combinations used in the therapy of methicillin-resistant Staphylococcus aureus (MRSA) infections, vancomycin plus either gentamicin or rifampin. Community-associated MRSA were more likely to be synergistically inhibited by combinations of vancomycin and gentamicin versus vancomycin alone compared to inhibition associated with hospital-acquired strains.",

author = "Samuel Shelburne and Musher, {Daniel M.} and Kristina Hulten and Heather Ceasar and Lu, {Michael Y.} and Imran Bhaila and Hamill, {Richard J.}",

year = "2004",

month = oct,

doi = "10.1128/AAC.48.10.4016-4019.2004",

language = "English (US)",

volume = "48",

pages = "4016--4019",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "10",

}

TY - JOUR

T1 - In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations

AU - Shelburne, Samuel

AU - Musher, Daniel M.

AU - Hulten, Kristina

AU - Ceasar, Heather

AU - Lu, Michael Y.

AU - Bhaila, Imran

AU - Hamill, Richard J.

PY - 2004/10

Y1 - 2004/10

N2 - This study employs time-kill techniques to examine the most common drug combinations used in the therapy of methicillin-resistant Staphylococcus aureus (MRSA) infections, vancomycin plus either gentamicin or rifampin. Community-associated MRSA were more likely to be synergistically inhibited by combinations of vancomycin and gentamicin versus vancomycin alone compared to inhibition associated with hospital-acquired strains.

AB - This study employs time-kill techniques to examine the most common drug combinations used in the therapy of methicillin-resistant Staphylococcus aureus (MRSA) infections, vancomycin plus either gentamicin or rifampin. Community-associated MRSA were more likely to be synergistically inhibited by combinations of vancomycin and gentamicin versus vancomycin alone compared to inhibition associated with hospital-acquired strains.

UR - http://www.scopus.com/inward/record.url?scp=4644289918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644289918&partnerID=8YFLogxK

U2 - 10.1128/AAC.48.10.4016-4019.2004

DO - 10.1128/AAC.48.10.4016-4019.2004

M3 - Article

C2 - 15388469

AN - SCOPUS:4644289918

VL - 48

SP - 4016

EP - 4019

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 10

ER -